News
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
IMV Inc. Announces Changes to Its Board of Directors
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today
Transgene Announces Upcoming Investor Meetings
Regulatory News:
TRANSGENE (Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that Management will participate in
Uni-Bio Science Group Limited: 2022 Annual Results
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
EQS-News: Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business
Evolva publishes agenda for 2023 Annual General Meeting
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance
Poxel will Report its 2022 Full Year Results on March 23, 2023
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Convatec Group PLC: Annual Report and Accounts 2022 and Notice of AGM
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Poxel to Report its 2022 Full Year Results by the End of March 2023
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2023. The purpose of